This New Oral Pill Could Make Lowering LDL Cholesterol Easier

Millions of Americans manage high cholesterol with daily medication, yet many struggle to reach their targets with statins alone. A new drug, Lipfendra, now provides an oral alternative for those who need more aggressive treatment. This medication is the first oral PCSK9 inhibitor approved by the FDA for the treatment of high LDL cholesterol.

Clinical trials involving over 3,000 adults showed that Lipfendra significantly lowers LDL levels. Participants taking the drug alongside statins experienced reductions in bad cholesterol by 56% to 59% compared to those on a placebo. This offers a new option for patients who require more than just statins but prefer to avoid regular injections.

While injectable PCSK9 inhibitors have existed for a decade, they are often underutilized in clinical practice. The arrival of an oral pill aims to remove the barrier of injection-based therapy for many patients. The medication works by blocking the PCSK9 protein, which allows the liver to clear more LDL cholesterol from the blood.

Lipfendra is indicated for adults with high cholesterol or those with an inherited condition called heterozygous familial hypercholesterolemia. Doctors anticipate that patients currently on statins will continue that therapy in addition to starting this new pill, as the drugs offer complementary benefits. Merck reports that a 30-day supply will cost 315 dollars before insurance adjustments, making it a competitive option in the market.